Cargando…
Lutetium-177-PSMA-617: A Vision of the Future
In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[(177)Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890398/ https://www.ncbi.nlm.nih.gov/pubmed/35220877 http://dx.doi.org/10.1080/15384047.2022.2037985 |